Stockscreener 앱 받기
16.80
5.69%
0.905
시간 외 거래:
16.90
0.095
+0.57%
전일 마감가:
$15.90
열려 있는:
$18.1
하루 거래량:
1.65M
Relative Volume:
1.43
시가총액:
$187.25M
수익:
-
순이익/손실:
$-121.02M
주가수익비율:
-1.4925
EPS:
-11.26
순현금흐름:
$-114.09M
1주 성능:
-0.21%
1개월 성능:
-9.75%
6개월 성능:
-39.98%
1년 성능:
+28.18%
1일 변동 폭
$16.27
$18.30
1주일 범위
$15.50
$18.34
52주 변동 폭
$7.31
$130.00
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Company Profile
명칭
Tonix Pharmaceuticals Holding Corp
전화
212-980-9155
주소
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
16.80 | 187.25M | 0 | -121.02M | -114.09M | -11.26 |
|
ARGX
Argen X Se Adr
|
929.61 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.02 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.40 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
376.63 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.31 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
토닉스 파마슈티컬스 홀딩 Stock (TNXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-04-18 | 개시 | Noble Capital Markets | Outperform |
| 2019-04-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2017-08-18 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2016-09-07 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 재확인 | Oppenheimer | Outperform |
| 2015-11-04 | 개시 | Cantor Fitzgerald | Buy |
| 2015-06-12 | 개시 | Oppenheimer | Outperform |
| 2015-02-17 | 재확인 | ROTH Capital | Buy |
| 2014-09-29 | 재확인 | ROTH Capital | Buy |
모두보기
토닉스 파마슈티컬스 홀딩 주식(TNXP)의 최신 뉴스
Tonix set for best day in over two months as new fibromyalgia drug hits U.S. market - TradingView
Tonix Pharmaceuticals stock rises as TONMYA becomes available for fibromyalgia - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Launches Fibromyalgia Treatment TON - GuruFocus
Tonix Pharma Launches TONMYA Tablets in U.S. - TipRanks
Tonix’s first FDA-approved fibromyalgia drug in 15 years now available - Investing.com India
Tonix Pharmaceuticals teams up with MGH to advance Phase 2 trial of TNX-1500 - Proactive financial news
Tonix Pharmaceuticals Announces U.S. Availability of TONMYA for Fibromyalgia - TradingView
Tonix Pharma (Nasdaq: TNXP) Makes TONMYA Non-Opioid Fibromyalgia Drug Available - Stock Titan
Risk vs reward if holding onto Tonix Pharmaceuticals Holding Corp.July 2025 Review & Free Technical Pattern Based Buy Signals - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver shareholder valueJuly 2025 Big Picture & Technical Pattern Recognition Alerts - newser.com
How Tonix Pharmaceuticals Holding Corp. stock responds to policy changesGap Up & Safe Entry Trade Signal Reports - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Raised to "Hold" at Wall Street Zen - MarketBeat
Volatility clustering patterns for Tonix Pharmaceuticals Holding Corp.2025 Price Action Summary & Weekly Consistent Profit Watchlists - newser.com
Will Tonix Pharmaceuticals Holding Corp. stock deliver strong dividend growthJuly 2025 Levels & Weekly Momentum Stock Picks - newser.com
Tonix Pharmaceuticals Holding Corp. stock trend forecastPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - newser.com
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook (NASDAQ:TNXP) - Seeking Alpha
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News - Yahoo Finance
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results - MarketBeat
Tonix Readies First New Fibromyalgia Drug In 15 Years - Finimize
Can Tonix Pharmaceuticals Holding Corp. stock deliver strong Q4 earningsQuarterly Profit Report & AI Optimized Trade Strategies - newser.com
Real time alert setup for Tonix Pharmaceuticals Holding Corp. performancePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Tonix Pharmaceuticals (TNXP) Q3 Revenue Surpasses Expectations - GuruFocus
Tonix Pharmaceuticals Reports Q3 2025 Earnings and Strategic Developments - TipRanks
Tonix Pharmaceuticals (TNXP) Q3 Earnings: Revenue Beats, EPS Mis - GuruFocus
Tonix Pharma earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Tonix Pharma earnings matched, revenue topped estimates - Investing.com
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights - The Manila Times
Tonix Pharmaceuticals Q3 net loss widens - MarketScreener
Tonix Pharmaceuticals Set to Launch Tonmya™ for Fibromyalgia Treatment, First New FDA-Approved Medicine in Over 15 Years - Quiver Quantitative
Is Tonix Pharmaceuticals Holding Corp. stock a safe haven assetMarket Trend Summary & High Accuracy Investment Signals - newser.com
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference - The Manila Times
How to build a dashboard for Tonix Pharmaceuticals Holding Corp. stockIndex Update & Low Drawdown Trading Techniques - newser.com
토닉스 파마슈티컬스 홀딩 (TNXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.99%
1.33%
자본화:
|
볼륨(24시간):